Background on the Rationale for the NATALEE Study

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • Patients diagnosed with estrogen receptor (ER)-positive breast cancer receive standard-of-care adjuvant treatment:
    • However, patients can experience disease recurrence:
      • With many recurrences occurring within the first 5 years
  • When disease recurrence does occur, it is often at a more advanced stage when the disease may be incurable:
    • Therefore, it is critical to prevent recurrences to better reach the original curative intent of treatment
  • Prior research demonstrated that ribociclib plus endocrine therapy:
    • Yielded significant improvements in overall and progression-free survival in patients with HR-positive / HER2-negative advanced breast cancer:
      • Based on that, NATALEE was designed to evaluate the combination in patients with early-stage disease
  • Another CDK4/6 inhibitor, abemaciclib, is U.S. Food and Drug Administration (FDA) approved for adjuvant treatment of adult patients with HR-positive / HER2-negative, node-positive early breast cancer at high risk of recurrence
  • What NATALEE now does:
    • If the FDA acknowledges the data for registration:
      • It enlarges the patient population who will have access to a CDK4/6 inhibitor
#Arrangoiz #CancerSurgeon #BreastSurgeon #SurgicalOncologist #BreastCancer #MountSiniaMedicalCenter #MSMC #Miami #Mexico
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment